Systematic Review of Preferences for Preexposure Prophylaxis Among Persons Assigned Male at Birth in the United States.

J Assoc Nurses AIDS CareMay 28, 2026 (epub)
Clinical ResearchInfectious Diseases

Amit Mickey Dhir, Steven J Clipman, Jason E Farley et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined preferences for preexposure prophylaxis (PrEP) among individuals assigned male at birth in the United States, focusing on men who have sex with men (MSM). The review included 10 studies, revealing that cost, dosing frequency, and side effects significantly influenced PrEP uptake. The findings highlight barriers to PrEP engagement, including stigma and misinformation.

Key findings

  • Cost, dosing frequency, and side effects were the most influential factors for MSM PrEP uptake.
  • Only 10 studies met inclusion criteria from an initial 648 records reviewed.
  • All included studies focused on men who have sex with men, with no representation of transgender women.
  • Subgroup differences by race, age, and geography were rarely explored.

Why it matters

Understanding preferences for PrEP among MSM is critical for improving uptake and addressing barriers. This knowledge can inform targeted interventions and enhance the effectiveness of HIV prevention strategies.

Source

PubMed · PMID 42214698

Published in J Assoc Nurses AIDS Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.